Endocrinology, Vol 122, 3008-3010, Copyright © 1988 by Endocrine Society

ARTICLES

The 7-34-fragment of human hypercalcemia factor is a partial agonist/antagonist for parathyroid hormone-stimulated cAMP production

RL McKee, ME Goldman, MP Caulfield, PA DeHaven, JJ Levy, RF Nutt and M Rosenblatt
Parathyroid Hormone Laboratory, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.

The N-terminal fragment of human hypercalcemia factor (hHCF), hHCF-(1- 34)NH2, has bioactivities similar to PTH in vitro and in vivo. Because it interacts with PTH receptors and is more potent than PTH in some systems, the hHCF sequence may provide interesting leads for the design of potent and selective PTH and hHCF antagonists. Based on the antagonist activity of [Tyr34]bovine PTH-(7-34)NH2 [( Tyr34]bPTH-(7- 34)NH2), we synthesized the corresponding fragment of hHCF, hHCF-(7- 34)NH2 and examined its properties in vitro. In the bone-derived rat osteosarcoma cell line ROS 17/2.8, hHCF-(7-34)NH2 and [Tyr34]bPTH-(7- 34)NH2 were equipotent for inhibition of radiolabeled PTH-binding. In contrast, hHCF-(7-34)NH2 was 8-fold more potent that [Tyr34]bPTH-(7- 34)NH2 for inhibiting PTH-stimulated cAMP production. hHCF-(7-34)NH2 also inhibited PTH-binding and PTH-stimulated adenylate cyclase activity in bovine renal cortical membranes: hHCF-(7-34)NH2 and [Tyr34]bPTH-(7-34)NH2 were equipotent in this system. In addition, hHCF- (7-34)NH2 antagonized hHCF-(1-34)NH2 action in both systems with similar inhibition constants. However, unlike the PTH analogue, hHCF-(7- 34)NH2 (8 microM) was a weak partial agonist, producing a 2.4-fold increase in cAMP (5% of the maximal response) in ROS cells. This same system also detects agonism for [Nle8, 18Tyr34]bPTH-(3-34)NH2, another PTH partial agonist/antagonist. These results demonstrate that hHCF-(7- 34)NH2 interacts with PTH receptors based in large part on the region which is not homologous to PTH, and suggest the utility of the ROS 17/2.8 cell system for identifying weak agonism of PTH and hHCF analogues in vitro.

This article has been cited by other articles:

				H. Degenhardt, J. Jansen, R. Schulz, D. Sedding, R. Braun-Dullaeus, and K.-D. Schluter Mechanosensitive release of parathyroid hormone-related peptide from coronary endothelial cells Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1489 - H1496. [Abstract] [Full Text] [PDF]

				S. R. J. Hoare and T. B. Usdin Tuberoinfundibular Peptide (7-39) [TIP(7-39)], a Novel, Selective, High-Affinity Antagonist for the Parathyroid Hormone-1 Receptor with No Detectable Agonist Activity J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 761 - 770. [Abstract] [Full Text]

				P. H. Carter, H. Jüppner, and T. J. Gardella Studies of the N-Terminal Region of a Parathyroid Hormone-Related Peptide(1-36) Analog: Receptor Subtype-Selective Agonists, Antagonists, and Photochemical Cross-Linking Agents Endocrinology, November 1, 1999; 140(11): 4972 - 4981. [Abstract] [Full Text]

				A. E. Adams, A. Bisello, M. Chorev, M. Rosenblatt, and L. J. Suva Arginine 186 in the Extracellular N-Terminal Region of the Human Parathyroid Hormone 1 Receptor Is Essential for Contact with Position 13 of the Hormone Mol. Endocrinol., November 1, 1998; 12(11): 1673 - 1683. [Abstract] [Full Text]

				J. A. Barden, R. M. Cuthbertson, W. Jia-Zhen, J. M. Moseley, and B. E. Kemp Solution Structure of Parathyroid Hormone Related Protein (Residues 1-34) Containing an Ala Substituted for an Ile in Position 15 (PTHrP[Ala15]-(1-34)) J. Biol. Chem., November 21, 1997; 272(47): 29572 - 29578. [Abstract] [Full Text] [PDF]

				T. J. Gardella, M. D. Luck, A. K. Wilson, H. T. Keutmann, S. R. Nussbaum, J. T. Potts Jr., and H. M. Kronenberg Parathyroid Hormone (PTH)-PTH-related Peptide Hybrid Peptides Reveal Functional Interactions between the 1-14 and 15-34 Domains of the Ligand J. Biol. Chem., March 24, 1995; 270(12): 6584 - 6588. [Abstract] [Full Text] [PDF]